Los puntos clave no están disponibles para este artículo en este momento.
C LINICAL INDICATIONS for use of recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) have expanded considerably since the drug first became available in the early 1990s for acceleration of myeloid engraftment in neutropenic patients. Initial clinical trials of rHuGM-CSF
Jamés O. Armitage (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: